Advertisement
Home »

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.

Jan 30, 2023

ABOUT THE CONTRIBUTORS

  • T M Davidson

    Division of Oncology, Mayo Clinic, Rochester, MN, USA.

    C L Lebreton

    Centre Léon Bérard, Lyon, France.

    A E Wahner Hendricksen

    Division of Oncology, Mayo Clinic, Rochester, MN, USA.

    H J Atkinson

    Division of Clinical Trials and Biostatistics, Department of Quantitative Health Science, Mayo Clinic, Rochester, MN, USA.

    M C Larson

    Division of Clinical Trials and Biostatistics, Department of Quantitative Health Science, Mayo Clinic, Rochester, MN, USA.

    A L Oberg

    Division of Computational Biology, Department of Quantitative Health Science, Mayo Clinic, Rochester, MN, USA.

    D M Provencher

    CHUM – Pavillon Notre-Dame, Montréal, QC, Canada.

    J A Glaspy

    Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA.

    B Y Karlan

    Division of Gynecologic Oncology, University of California Los Angeles, Los Angeles, CA, USA.

    D J Slamon

    Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA.

    G E Konecny

    Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA; Division of Gynecologic Oncology, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: gkonecny@mednet.ucla.edu.

    I L Ray-Coquard

    Centre Léon Bérard, Lyon, France; Health Services and Performance Research Lab (EA 7425 HESPER), University Claude Bernard Lyon 1, 69008 Lyon, France.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement